Furthermore, GDF-15 also contributed to the development of NAFLD by reducing the number of CD80 on plasmacytoid DCs and CD80 on CD62L+ plasmacytoid DCs, mediating 13.98% and 13.95% of the total effect, respectively (Table 1). The gene discussed is SELL; the disease is metabolic dysfunction-associated steatotic liver disease.